Her PBC Drug Was Withdrawn From the Market While She Was Responding to It
A patient doing well on obeticholic acid for primary biliary cholangitis needs a new second-line agent after the drug's voluntary US withdrawal. The pivot isn't whether to switch — it's which of two newer, less-established options actually fits a patient who was, until this week, a treatment success.
Constance O., a 63-year-old woman, retired two years ago from three decades as a public librarian and now spends most of her time in her garden and with her three grandchildren, who live nearby. She was diagnosed with primary biliary cholangitis five years ago after a routine physical found an elevated alkaline phosphatase, and has been on ursodeoxycholic acid since diagnosis; obeticholic acid was added eighteen months ago after her alkaline phosphatase failed to normalize on UDCA alone. On the combination, her alkaline phosphatase fell from 340 to 165, a genuine treatment response by the biochemical criteria her hepatologist uses to judge second-line therapy, and her mild pruritus, present since diagnosis, has stayed stable rather than worsening. She has no cirrhosis on her most recent imaging and no history of decompensation.
None of that changes the fact that obeticholic acid is no longer available in the United States, voluntarily withdrawn from the market in 2025 after a post-marketing safety signal, leaving her without her actual second-line drug despite being, on paper, exactly the kind of biochemical responder that second-line therapy is supposed to produce. Two PPAR-pathway agonists, elafibranor and seladelpar, were granted accelerated approval for the same indication in 2024 on the strength of ELATIVE and RESPONSE respectively — both, like obeticholic acid's own POISE, on an alkaline-phosphatase surrogate rather than a clinical outcome. Neither carries obeticholic acid's years of accumulated real-world follow-up in a patient who is not starting second-line therapy fresh — she is trying to hold onto a response she already has.
Choosing a replacement, not starting fresh
I'd move her to elafibranor. It was the first of the two newer PPAR agonists approved for this exact second-line indication, and it simply has more real-world follow-up behind it at this point than seladelpar does. All else being reasonably close between the two, I'd rather have the longer track record for a patient who's already shown she responds well to combination therapy.
Track record is a fair tiebreaker, but I don't think this is actually a close call once you weigh her symptom profile. RESPONSE showed a meaningfully better effect for seladelpar on pruritus specifically — the one endpoint on which obeticholic acid reliably went the wrong way, and pruritus — not biochemical response — is what actually drives PBC patients to quietly stop taking a medication that's working on paper.
Her pruritus is stable, not the dominant complaint yet, which is exactly why leaning on longer follow-up over an unrealized symptom benefit isn't unreasonable — but 'not yet dominant' isn't the same as 'won't become relevant once she's on a new drug and adjusting to it.'
Whichever of you is right, I'd flag something neither position addresses: we're switching and stopping obeticholic acid in the same visit, with no interim biochemical data point in between. If her alkaline phosphatase moves in either direction over the next few months, we won't cleanly know whether that's the new drug working, the new drug underperforming, or just normal fluctuation off a drug she'd been stable on for a year and a half. I'd draw today's labs as the explicit new baseline and say so in the chart, regardless of which agent she starts.
Switched to elafibranor plus continued UDCA, with today's alkaline phosphatase and bilirubin documented explicitly as the new baseline against obeticholic acid's own last measured values.
Follow-up labs planned at 8 weeks rather than the usual 12, specifically to catch an early divergence from her prior response while it's still easy to interpret against a clean starting point.